Literature DB >> 22306512

Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis.

HongYan Jiang1, Rong Xiao, XiaoRi Lian, Takuro Kanekura, YangYang Luo, YongXing Yin, GuiYing Zhang, Yan Yang, YaoYao Wang, Ming Zhao, QianJin Lu.   

Abstract

The pathogenesis of systemic sclerosis (SSc) is still unclear. CD70, a B cell costimulatory molecule that interacts with CD27 during B-T cell contact, is overexpressed due to demethylation of its promoter regulatory elements in CD4+ T cells from patients with the following autoimmune diseases, namely systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and primary Sjögren's syndrome (pSS). However, as an autoimmune disease, it is unknown whether aberrant expression and methylation of CD70 occur in SSc CD4+ T cells. We aimed to investigate whether the aberrant expression and methylation status of CD70 occur in CD4+ T cells from patients with SSc. We found that the CD70 is overexpressed and the CD70 promoter region is demethylated in SSc CD4+ T cells. These findings suggest that demethylation of CD70 promoter region contributes to the overexpression of CD70 in CD4+ T cells and may contribute to autoimmune response in SSc. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306512     DOI: 10.1016/j.clim.2012.01.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  23 in total

Review 1.  Epigenetics and systemic sclerosis.

Authors:  Nezam Altorok; Bashar Kahaleh
Journal:  Semin Immunopathol       Date:  2015-07-11       Impact factor: 9.623

Review 2.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

3.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 4.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

Review 5.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  J Autoimmun       Date:  2017-05-16       Impact factor: 7.094

Review 6.  The role of genetics and epigenetics in the pathogenesis of systemic sclerosis.

Authors:  Jasper C A Broen; Timothy R D J Radstake; Marzia Rossato
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 7.  Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Expert Rev Clin Immunol       Date:  2015-01       Impact factor: 4.473

Review 8.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 9.  The multifaceted functional role of DNA methylation in immune-mediated rheumatic diseases.

Authors:  Matteo Vecellio; Haijing Wu; Qianjin Lu; Carlo Selmi
Journal:  Clin Rheumatol       Date:  2020-07-02       Impact factor: 2.980

Review 10.  Emerging role of epigenetics in systemic sclerosis pathogenesis.

Authors:  M Ciechomska; J M van Laar; S O'Reilly
Journal:  Genes Immun       Date:  2014-07-17       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.